NCT01519778 - A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

February 15, 2012

Primary Completion Date

August 27, 2012

Study Completion Date

August 27, 2012

Conditions

Major Cutaneous AbscessCellulitisErysipelas

Interventions

DRUG

TR701 FA

1 tablet 200 mg once daily

Trial Locations (10)

Trius Investigator Site 102, Savannah

Trius Investigator Site 101, Columbus

Trius Investigator Site 128, Las Vegas

Trius Investigator Site #129, Buena Park

Trius Investigator Site #106, Long Beach

Trius Investigator Site 103, Chula Vista

Trius Investigator Site 105, La Mesa

Trius Investigator Site 104, Oceanside

Trius Investigator Site #118, Anaheim

Trius Investigator Site 115, Somers Point